American Society of Hematology, 2025 (ASH)
7 - 9 December 2025
Mim8 prophylaxis in adults and adolescents with Hemophilia A: 52-week efficacy and safety outcomes from the Phase 3 FRONTIER2 study
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.